In cancer cell lines, SMYD3-mediated methylation of MAP3K2 at lysine 260 enhances activation of the Ras/Raf/MEK/ERK signaling and SMYD3 depletion synergizes with a MEK inhibitor to block Ras-driven tumors. Here, SMYD3 is linked to cancer.